Predispositions to Lymphoma: A Practical Review for Genetic Counselors

Journal of Genetic Counseling

Volumn 25, Issue 6, 2016, Pages 1157-1170

  Similuk, Morgan ^a   Rao, V Koneti ^a   Churpek, Jane ^b   Lenardo, Michael ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Cancer; Genetic counseling; Heredity; Immunology; Lymphoma; Mechanism; Predisposition; Risk assessment

Indexed keywords

FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; LYMPHOMA; MALE; PRACTICE GUIDELINE; RISK ASSESSMENT;

FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; LYMPHOMA; MALE; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 84995794380     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-016-9979-0     Document Type: Review

References (82)

1. Alkhairy, O. K., Perez-Becker, R., Driessen, G. J., Abolhassani, H., van Montfrans, J., Borte, S., et al. (2015). Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and genetic characterization of human CD27 deficiency. Journal of Allergy and Clinical Immunology, 136(3), 703–712.e710.
2. Angulo, I., Vadas, O., Garçon, F., Banham-Hall, E., Plagnol, V., Leahy, T. R., et al. (2013). Phosphoinositide 3-kinase δ Gene mutation predisposes to respiratory infection and airway damage. Science, 342, 866–871.
3. Austin, J. C. (2010). Re-conceptualizing risk in genetic counseling: implications for clinical practice. Journal of Genetic Counseling, 19, 228–234.
4. Aydin, S. E., Kilic, S. S., Aytekin, C., Kumar, A., Porras, O., Kainulainen, L.,. Albert, M. H. (2015). DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients. Journal of Clinical Immunology, 35, 189–198.
5. Bansidhar, B. J. (2012). Extracolonic manifestations of lynch syndrome. Clinics in Colon and Rectal Surgery, 25(2), 103–110.
6. Bienemann, K., Borkhardt, A., Klapper, W., & Oschlies, I. (2015). High incidence of Epstein-Barr virus (EBV)-positive Hodgkin lymphoma and Hodgkin lymphoma-like B-cell lymphoproliferations with EBV latency profile 2 in children with interleukin-2-inducible T-cell kinase deficiency (pp. 1–10). Epub: Histopathology.
7. Biesecker, B. B., Schwartz, M. D., & Marteau, T. M. (2013). Enhancing informed choice to undergo health screening: a systematic review. American Journal of Health Behavior, 37, 351–359.
8. Birch, J. M., Alston, R. D., McNally, R. J., Evans, D. G., Kelsey, a. M., Harris, M.,. Varley, J. M. (2001). Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene, 20, 4621–4628.
9. Booth, C., Gilmour, K. C., Veys, P., Gennery, A. R., Slatter, M. a., Chapel, H., et al. (2010). X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management, and outcome of the disease. Blood, 117, 53–63.
10. Caporaso, N. E., Goldin, L. R., Anderson, W. F., & Landgren, O. (2009). Current insight on trends, causes, and mechanisms of Hodgkin's lymphoma. Cancer Journal, 15(2), 117–123.
11. Chiu, B. C., & Hou, N. (2015). Epidemiology and etiology of non-Hodgkin lymphoma. Cancer Treatment and Research, 165, 1–25.
12. Chua, I., Quinti, I., & Grimbacher, B. (2008). Lymphoma in common variable immunodeficiency: interplay between immune dysregulation, infection and genetics. Current Opinion in Hematology, 15, 368–374.
13. Churpek, J. E., & Onel, K. (2010). Heritability of hematologic malignancies: from pedigrees to genomics. Hematology/Oncology Clinics of North America, 24, 939–972.
14. Churpek, J. E., Lorenz, R., Nedumgottil, S., Onel, K., Olopade, O. I., Sorrell, A.,. Godley, L. a. (2013). Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leukemia and Lymphoma, 54, 28–35.
15. Clementi, R., Locatelli, F., Dupré, L., Garaventa, A., Emmi, L., Bregni, M.,. Roncarolo, M. G. (2005). A proportion of patients with lymphoma may harbor mutations of the perform gene. Blood, 105, 4424–4428.
16. Crank, M., Grossman, J., Moir, S., Pittaluga, S., Buckner, C., Kardava, L.,. Rosenzweig, S. (2014). Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. Journal of Clinical Immunology, 34, 272–276.
17. Cunningham-Rundles, C. (2012). The many faces of common variable immunodeficiency. Hematology, 301–305.
18. Daly, M. B., Lerman, C. L., Ross, E., Schwartz, M. D., Sands, C. B., & Masny, A. (1996). Gail model breast cancer risk components are poor predictors of risk perception and screening behavior. Breast Cancer Research and Treatment, 41, 59–70.
19. Ehrenfeld, M., Abu-Shakra, M., Buskila, D., & Shoenfeld, Y. (2001). The dual association between lymphoma and autoimmunity. Blood Cells, Molecules & Diseases, 27, 750–756.
20. Ellis, C. N. (2010). Inherited Cancer Syndromes: Current Clinical Management. C. N. Ellis Ed. 2nd (Edition ed.). New York: Springer.
21. Fagerline, A., Zikmund-Fisher, B. J., & Ubel, P. A. (2011). Helping patients decide: ten steps to better risk communication. Journal of the National Cancer Institute, 103, 1–8.
22. Fisher, S. G., & Fisher, R. I. (2004). The epidemiology of non-Hodgkin's lymphoma. Oncogene, 23, 6524–6534.
23. Flanagan, S. E., Haapaniemi, E., Russell, M. a., Caswell, R., Allen, H. L., De Franco, E.,. Hattersley, A. T. (2014). Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nature Genetics, 46, 812–814.
24. Folkman, S. (1984). Personal control and stress and coping processes: a theoretical analysis. Journal of Personality and Society Psychology, 46, 4:839-852.
25. Gatti, R. A., & Good, R. A. (1971). Occurrence of malignancy in immunodeficiency diseases. Cancer, 28(89–99).
26. German, J. (1997). Bloom's syndrome: the first 100 cancers. Cancer Genetics and Cytogenetics, 93, 100–106.
27. Ghosh, S., Bienemann, K., Boztug, K., & Borkhardt, A. (2014). Interleukin-2-inducible T-cell kinase (ITK) deficiency - clinical and molecular aspects. Journal of Clinical Immunology, 34, 892–899.
28. Goldgar, D. E., Easton, D. F., Cannon-Albright, L. a., & Skolnick, M. H. (1994). Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. JNCI Journal of the National Cancer Institute, 86, 1600–1608.
29. Goldin, L. R., Landgren, O., McMaster, M. L., Gridley, G., Hemminki, K., Li, X., et al. (2005). Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples. Cancer Epidemiology, Biomarkers & Prevention, 14, 2402–2406.
30. Gonzalez, K. D., Noltner, K. a., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., et al. (2009). Beyond Li-Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. Journal of Clinical Oncology, 27, 1250–1256.
31. Gooding, H. C., Organista, K., Burack, J., & Biesecker, B. B. (2006). Genetic susceptibility testing from a stress and coping perspective. Social Science & Medicine (1982), 62, 1880–1890.
32. Grover, S., Stoffel, E. M., Bussone, L., Tschoegl, E., & Syngal, S. (2004). Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clinical Gastroenterology and Hepatology, 2, 813–819.
33. Hirbod-Mobarakeh, A., Aghamohammadi, A., & Rezaei, N. (2014). Immunoglobulin class switch recombination deficiency type 1 or CD40 ligand deficiency: from bedside to bench and back again. Expert Review of Clinical Immunology, 10(1), 91–105.
34. Holmfeldt, L., Wei, L., Diaz-Flores, E., Walsh, M., Zhang, J., Ding, L., et al. (2013). The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nature Genetics, 45(3), 242–252.
35. Hughes, C., Lerman, C., Schwartz, M., Peshkin, B. N., Wenzel, L., Narod, S., et al. (2002). All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results. American Journal of Medical Genetics, 107, 143–150.
36. Kanegane, H., Yang, X., Zhao, M., Yamato, K., Inoue, M., Hamamoto, K., et al. (2012). Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis. Pediatric Allergy and Immunology, 23, 488–493.
37. Kondratenko, I., Paschenko, O., Polyakov, A., & Bologov, A. (2000). Nijmegen breakage syndrome. Archives of Diseases in Childhood, 82, 400–406.
38. Kuehn, H. S., Ouyang, W., Lo, B., Deenick, E. K., Niemela, J. E., Avery, D. T., et al. (2013). Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science, 345, 1623–1627.
39. Leechawengwongs, E., & Shearer, W. T. (2012). Lymphoma complicating primary immunodeficiency syndromes. Current Opinion in Hematology, 19, 305–312.
40. Li, F.-Y., Chaigne-Delalande, B., Kanellopoulou, C., Davis, J. C., Matthews, H. F., Douek, D. C.,. Lenardo, M. J. (2011). Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature, 475, 471–476.
41. Li, F.-Y., Chaigne-Delalande, B., Su, H., Uzel, G., Matthews, H., & Lenardo, M. J. (2014). XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood, 123, 2148–2152.
42. Lipinski, S. E., Lipinski, M. J., Biesecker, L. G., & Biesecker, B. B. (2006). Uncertainty and perceived personal control among parents of children with rare chromosome conditions: the role of genetic counseling. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 142C(4), 232–240.
43. Lucas, C. L., Kuehn, H. S., Zhao, F., Niemela, J. E., Deenick, E. K., Palendira, U., et al. (2014). Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nature Immunology, 15, 88–97.
44. Mackay, I. R., & Rose, N. R. (2001). Autoimmunity and lymphoma: tribulations of B cells. Nature Immunology, 2, 793–795.
45. Milner, J. D., & Holland, S. M. (2013). The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Nature Reviews Immunology, 13, 635–648.
46. Milner, J. D., Vogel, T. P., Forbes, L., Ma, C. A., Stray-Pedersen, A., Niemela, J. E.,. Cooper, M. A. (2015). Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood, 125(4), 591–599.
47. Mitchell, J. M., & Conklin, E. A. (2015). Factors affecting receipt of expensive cancer treatments and mortality: evidence from stem cell transplantation for leukemia and lymphoma. Health Services Research, 50(1), 197–216.
48. Murff, H. J., Byrne, D., & Syngal, S. (2004). Cancer risk assessment: quality and impact of the family history interview. American Journal of Preventive Medicine, 27, 239–245.
49. Murphy, K. (2012). Janeway's Immunobiology (8th ed.). London and New York: Garland Science.
50. Ngalamika, O., Zhang, Y., Yin, H., Zhao, M., Gershwin, M. E., & Lu, Q. (2012). Epigenetics, autoimmunity and hematologic malignancies: a comprehensive review. Journal of Autoimmunity, 39, 451–465.
51. Ochs, H. D., & Thrasher, A. J. (2006). The Wiskott-Aldrich syndrome. Journal of Allergy and Clinical Immunology, 117(4), 725–738 quiz 739.
52. Pachlopnik Schmid, J., Canioni, D., Moshous, D., Touzot, F., Mahlaoui, N., Hauck, F.,. Latour, S. (2011). Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood, 117(5), 1522–1529.
53. Patenaude, A. F., Dorval, M., DiGianni, L. S., Schneider, K. a., Chittenden, A., & Garber, J. E. (2006). Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. Journal of Clinical Oncology, 24, 700–706.
54. Peshkin, B. N., DeMarco, T., & Tercyak, K. P. (2010). On the development of a decision support intervention for mothers undergoing BRCA1/2 cancer genetic testing regarding communicating test results to their children. Familial Cancer, 9, 89–97.
55. Poppema, S., Maggio, E., & Van Den Berg, A. (2004). Development of lymphoma in autoimmune lymphoproliferative syndrome (ALPS) and its relationship to FAS Gene mutations. Leukemia and Lymphoma, 45(3), 423–431.
56. Price, S., Shaw, P. A., Seitz, A., Joshi, G., Davis, J., Niemela, J. E., et al. (2014). Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood, 123, 1989–2000.
57. Ravell, J., Chaigne-Delalande, B., & Lenardo, M. (2014). X-linked immunodeficiency with magnesium defect, Epstein–Barr virus infection, and neoplasia disease. Current Opinion in Pediatrics, 26, 713–719.
58. Resta, R., Biesecker, B. B., Bennett, R. L., Blum, S., Hahn, S. E., Strecker, M. N.,.. Force, N. S. o. G. C. D. T. (2006). A new definition of genetic counseling: National Society of genetic Counselors' task force report. Journal of Genetic Counseling, 15(2), 77–83.
59. Rezaei, N., Hedayat, M., Aghamohammadi, A., & Nichols, K. E. (2011). Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. The Journal of Allergy and Clinical Immunology, 127, 1329–1341.e1322; quiz 1342-1323.
60. Rohr, J., Beutel, K., Maul-Pavicic, A., Vraetz, T., Thiel, J., Warnatz, K., et al. (2010). Atypical familial hemophagocytic lymphohistiocytosis due to mutations in UNC13D and STXBP2 overlaps with primary immunodeficiency diseases. Haematologica, 95, 2080–2087.
61. Rossi, D., Ciardullo, C., & Gaidano, G. (2013). Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next generation sequencing studies. Seminars in Cancer Biology, 23, 422–430.
62. Saarinen, S., Aavikko, M., Aittomaki, K., Launonen, V., Lehtonen, R., Franssila, K., et al. (2011). Exome sequencing reveals germline NPAT mutation as a candidate risk factor for Hodgkin lymphoma. Blood, 118(3), 493–498.
63. Salipante, S. J., Mealiffe, M. E., Wechsler, J., Krem, M. M., Liu, Y., Namkoong, S., et al. (2009). Mutations in a Gene encoding a Midbody Kelch protein in familial and sporadic classical Hodgkin lymphoma lead to Binucleated cells. Proceedings of the National Academy of Sciences of the United States of America, 106(35), 14920–14925.
64. Schneider, K. A. (2011). Counseling about Cancer: Strategies for Genetic Counseling K. A. Schneider Ed. 3rd (edition ed.). Hoboken, NJ: John Wiley & Sons.
65. Segel, G. (2004). Familial (inherited) leukemia, lymphoma, and myeloma: an overview. Blood Cells, Molecules, and Diseases, 32, 246–261.
66. Seidel, M. G. (2014). Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood, 124, 2337–2344.
67. Shiloh, S. (2006). Illness representations, self-regulation, and genetic counseling: a theoretical review. Journal of Genetic Counseling, 15(5), 325–337.
68. Siddiqui, R., Onel, K., Facio, F., & Offit, K. (2004). The genetics of familial lymphomas. Current Oncology Reports, 6(5), 380–387.
69. Snow, A. L., Xiao, W., Stinson, J. R., Lu, W., Chaigne-Delalande, B., Zheng, L., et al. (2012). Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. The Journal of Experimental Medicine, 209, 2247–2261.
70. Stern, M., Buser, A. S., Lohri, A., Tichelli, A., & Nissen-Druey, C. (2007). Autoimmunity and malignancy in hematology–more than an association. Critical Reviews in Oncology/Hematology, 63, 100–110.
71. Stiller, C. a., Chessells, J. M., & Fitchett, M. (1994). Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. British Journal of Cancer, 70, 969–972.
72. Straus, S. E. (2001). The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline FAS mutations and defective lymphocyte apoptosis. Blood, 98, 194–200.
73. Su, H. C., Jing, H., & Zhang, Q. (2011). DOCK8 deficiency. Annals of the New York Academy of Sciences, 1246, 26–33.
74. Suarez, F., Mahlaoui, N., Canioni, D., Andriamanga, C., Dubois d'Enghien, C., Brousse, N., et al. (2015). Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. Journal of Clinical Oncology, 33(2), 202–208.
75. Sullivan, K. E., Mullen, C. a., Blaese, R. M., & Winkelstein, J. a. (1994). A multiinstitutional survey of the Wiskott-Aldrich syndrome. Journal of Pediatrics, 125, 876–885.
76. Taylor, A., Metcalfe, J., Thick, J., & Mak, Y.-F. (1996). Leukemia and lymphoma in ataxia telangiectasia. Blood, 87, 423–438.
77. Tercyak, K. P., Peshkin, B. N., DeMarco, T. a., Brogan, B. M., & Lerman, C. (2002). Parent–child factors and their effect on communicating BRCA1/2 test results to children. Patient Education and Counseling, 47, 145–153.
78. Tran, H., Nourse, J., Hall, S., Green, M., Griffiths, L., & Gandhi, M. K. (2008). Immunodeficiency-associated lymphomas. Blood Reviews, 22, 261–281.
79. Vadaparampil, S. T., Malo, T., de la Cruz, C., & Christie, J. (2012). Do breast cancer patients tested in the oncology care setting share BRCA mutation results with family members and health care providers? Journal of Cancer Epidemiology, 2012, 1–10.
80. Vaqué, J. P., Martínez, N., Batlle-López, A., Pérez, C., Montes-Moreno, S., Sánchez-Beato, M., et al. (2014). B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica, 99, 222–231.
81. Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002). The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100(7), 2292–2302.
82. Wimmer, K., Kratz, C. P., Vasen, H. F., Caron, O., Colas, C., Entz-Werle, N., et al. (2014). Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the. European consortium 'care for CMMRD' Journal of Medical Genetics, 51(6), 355–365.